How It Works
Pricing
FAQ
AI Benchmark
Request a Demo
Don't Miss the Safety Signal That Matters
Capture 98% of PubMED articles containing adverse events with 100% reproducibility using the #1- ranked AI—scientifically proven by independent judges from NIH. Validate it yourself with complimentary credits—no credit card required.
PV AI Benchmark Initiative
To address the lack of transparent evaluation in AI-driven pharmacovigilance, we are processing the entire previous year of PubMed literature across all prescription drugs. By generating independent, AI-derived results from this historical corpus and releasing them as a reference dataset, we aim to establish the first industry-wide performance baseline for AI-based literature monitoring, enabling objective comparison, reproducibility, and more informed adoption of AI in drug safety.
Every Missed Safety Signal is a Risk You Can't Afford
Inconsistent Recall: Even skilled reviewers miss relevant studies, risking incomplete or biased conclusions.
High Operational Cost: Maintaining manual review typically requires 2+ full-time experts, costing ~$300,000 annually in salary and overhead.
Poor Scalability: Doubling your workload means doubling your team. There's no efficient way to scale without proportional increases in cost and coordination.
Extremely Time-Consuming: Teams spend over 40 hours per week per drug sifting through publications time.
The Most Accurate AI for Pharmacovigilance
Scientifically proven. Transparent. Risk-free to validate.
Scientifically Proven AI
#1 in Independent AI Competitions
Independent judges from NIH. Don't trust vendor claims—trust third-party validation.
BioCreative VIII BioRED Track Results (JZhangLab)98% Recall—Don't Miss Signals
Capture 98 out of 100 Papers with Adverse Events
IPV uses a recall-optimized search strategy + advanced AI to ensure you don't miss critical ADRs that matter.
Validated on 3,557 Annotated Abstracts
Transparent AI You Can Explain
Sentence-Level Evidence for Every Extraction
When FDA auditors ask "Why did your AI flag this article?", IPV shows the exact sentence and text evidence. No black boxes. Full traceability from MedDRA code → source sentence → PubMed article.
See Live DemoValidate Risk-Free with Free Credits
No Credit Card. No Sales Pressure.
Don't take our word for it—try IPV free with complimentary credits. Compare IPV to your current process. If IPV doesn't capture more signals with less work, don't buy it.
How IPV Works: Simple, Automated, Transparent
Define Your Drugs
Add drug names, aliases, and monitoring parameters.
Automated AI Screening
IPV automatically screens PubMed literature, identifies safety-relevant publications, extracts adverse events, and normalizes to MedDRA.
Review & Export Results
Review sentence-level evidence for each extraction. Export reports (spreadsheet) for regulatory submissions or integrate with your PV system.
Why IPV? Compare for Yourself
Capability
IPV
Pure Manual
LLM-only
Accuracy
High recall
Misses frequently
Variable
Explainability
Sentence-level evidence provided
Fully explainable (human-reviewed)
Limited or no traceable evidence ("black box")
Reproducibility
100% reproducible PubMed search results
Reproducible if documented carefully and precisely
Not reproducible (stochastic outputs)
Time
~4 hrs/week
~40 hrs/week
~5–10 hrs/week (plus validation overhead)
Cost
Starting at $2,000/month
~$25,000/month (2 FTEs)
$500–$5,000/month (API + engineering effort)
Scalability
Scales simply with demand
Poor, requires hiring more staff
Scales technically, but quality degrades
Simple, Transparent Pricing. No Surprises.
$25K per Drug per Year
Unlimited users, daily/weekly monitoring, MedDRA normalization, audit-ready documentation
Frequently Asked Questions
NIH LitCoin and BioCreative VIII ranked us #1 of 14 teams worldwide. Our 98% recall is validated on 3,557 annotated abstracts. But don't take our word—validate it yourself with up to 3 free drugs.
Learn More About BioCreative VIII BioRED Track →No, IPV complements your existing PV systems. Think of Oracle Argus as your system of record for case management, and IPV as your intelligence layer for literature monitoring. Most customers use both together—Argus for compliance, IPV for signal detection.
Yes. Every extracted adverse event includes the source PubMed article (PMID), the specific sentence where it was mentioned, and the text evidence that triggered the extraction. You can show auditors exactly why IPV flagged an article—no black boxes.
IPV provides traceability through metadata in reports (search parameters, timestamps, AI version). Full 21 CFR Part 11 compliance (audit trails, e-signature, change control) is on roadmap for Q3 2026. For enterprise customers, we provide validation support (IQ/OQ/PQ protocols). If you need immediate full compliance, we can discuss implementation timeline during demo.
Your 14-day free trial allows you to monitor up to 3 drugs. After the trial, you can upgrade to a paid plan.
Built for Regulatory Scrutiny
Scientific Validation
BioCreative Challenge VIII: #1
NIH LitCoin: #1
Peer-reviewed methodology
Published validation results
Regulatory Alignment
FDA/EMA reporting standards
MedDRA normalization
Audit-ready documentation
Validation support (IQ/OQ/PQ)
Data Security
Encrypted data storage
SOC 2 compliant (in progress)
HIPAA-ready infrastructure
Data portability (you own your data)
Transparency
Sentence-level evidence
Full audit trails (metadata)
Explainable AI decisions
No black boxes
Don't Miss Another Safety Signal. Validate IPV Today.
Join forward-thinking pharma and biotech companies using the most accurate AI for literature monitoring.
Schedule a Demo
See IPV in action with your drugs
Custom implementation plan
ROI analysis for your portfolio